A national strategy for the elimination of hepatitis B and C : phase two report / Gillian J. Buckley and Brian L. Strom, editors ; Committee on a National Strategy for the Elimination of Hepatitis B and C, Board on Population HBealth and Public Health Practice, Helath and Medicine Division ; a report of the National Academies of Sciences, Engineering, Medicine

Published: Washington, DC : The National Academies Press, [2017]
Copyright Date: ©2017
Physical Description: 1 online resource (xvi, 280 pages) : illustrations (some color)
Additional Creators: Buckley, Gillian J., Strom, Brian L., and National Academies of Sciences, Engineering, and Medicine (U.S.). Committee on a National Strategy for the Elimination of Hepatitis B and C

Access Online

ezaccess.libraries.psu.edu

Availability

Finding items...

Contents

Introduction -- Targets for elimination -- Public health information -- Essential interventions -- Service delivery -- Financing elimination -- Research -- Appendix A: Population health impact and cost-effectiveness of chronic hepatitis B diagnosis, care, and treatment in the United States -- Appendix B: Modeling the elmination of hepatitis C in the United States -- Appendix C: Public meeting agenda -- Appendix D: Committee biographies.

Summary

"Hepatitis B and C cause most cases of hepatitis in the United States and the world. The two diseases account for about a million deaths a year and 78 percent of world's hepatocellular carcinoma and more than half of all fatal cirrhosis. In 2013 viral hepatitis, of which hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most common types, surpassed HIV and AIDS to become the seventh leading cause of death worldwide. The world now has the tools to prevent hepatitis B and cure hepatitis C. Perfect vaccination could eradicate HBV, but it would take two generations at least. In the meantime, there is no cure for the millions of people already infected. Conversely, there is no vaccine for HCV, but new direct-acting antivirals can cure 95 percent of chronic infections, though these drugs are unlikely to reach all chronically-infected people anytime soon. This report, the second of two, builds off the conclusions of the first report and outlines a strategy for hepatitis reduction over time and specific actions to achieve them"--Publisher's description.

Subject(s)

ISBN

9780309457309 (electronic bk.)
0309457300 (electronic bk.)
9780309457293 (paperback)
0309457297 (paperback)

Bibliography Note

Includes bibliographical references.

Funding Information

"This acticivy was supported by the American Association for the Study of Liver Diseases, the Infectious Disseases Society of America, the National Viral Hepatitis Roudtable, and the U.S. Department of Health and Huyman Services/Centers for Disease Control and Prevention (Contract No. 200-2011-38807, Task Order #44. Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project"--Title page verso.

View MARC record | catkey: 43661475